Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Kim, Seoyoung C ^a   Landon, Joan E ^a   Lee, Yvonne C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DULOXETINE; GABAPENTIN; PREGABALIN; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; FEMALE; FIBROMYALGIA; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRESCRIPTION; HEALTH SERVICE; MIDDLE AGED; PATIENT ATTITUDE; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADULT; AMINES; AMITRIPTYLINE; ANALGESICS, NON-NARCOTIC; COHORT STUDIES; CYCLOHEXANECARBOXYLIC ACIDS; DULOXETINE HYDROCHLORIDE; FEMALE; FIBROMYALGIA; GAMMA-AMINOBUTYRIC ACID; HEALTH SERVICES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PREGABALIN;

EID: 84924297256     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0530-8     Document Type: Article

References (31)

1. Wolfe F. The epidemiology of fibromyalgia. J Musculoskelet Pain. 1993;1:137-48.
2. Wolfe F, Ross K, Anderson J, Russell I. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol. 1995;22:151-6.
3. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62:600-10.
4. Clauw D, Crofford L. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol. 2003;17:685-701.
5. Hassett AL, Gevirtz RN. Nonpharmacologic treatment for fibromyalgia: patient education, cognitive-behavioral therapy, relaxation techniques, and complementary and alternative medicine. Rheum Dis Clin North Am. 2009;35:393-407.
6. Häuser W, Bernardy K, Uçeyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin: a meta-analysis of randomized controlled trials. Pain. 2009;145:69-81.
7. Häuser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther. 2014;16:201.
8. White L, Robinson R, Yu A, Kaltenboeck A, Samuels S, Mallett D, et al. Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia. J Pain. 2009;10:976-83.
9. Robinson RL, Kroenke K, Williams DA, Mease P, Chen Y, Faries D, et al. Longitudinal observation of treatment patterns and outcomes for patients with fibromyalgia: 12-month findings from the reflections study. Pain Med. 2013;14:1400-15.
10. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ. 2012;15:19-31.
11. Peng X, Sun P, Novick D, Andrews J, Sun S. Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia. J Pain Res. 2014;7:37-46.
12. Sun P, Peng X, Sun S, Novick D, Faries DE, Andrews JS, et al. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators. Pain Pract. 2014;14:22-31.
13. Zhao Y, Sun P, Watson P, Mitchell B, Swindle R. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia. Pain Pract. 2011;11:204-16.
14. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants. J Med Econ. 2012;15:32-44.
15. Kim SC, Landon JE, Solomon DH. Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. Arthritis Care Res (Hoboken). 2013;65:1813-9. doi:10.1002/acr.22071.
16. Gore M, Sadosky A, Zlateva G, Clauw D. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin. Pain Pract. 2009;9:363-74.
17. Deyo R, Cherkin D, Ciol M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-9.
18. Schneeweiss S, Seeger J, Maclure M, Wang P, Avorn J, Glynn R. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001;154:854-64.
19. Rubin D. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-63.
20. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Sugi 26 Proceedings. Long Beach, CA. April 22-25, 2001 Cary, NC: SAS Institute. 2001. p. 214-26. http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed 30 January 2015.
21. Cameron AC, Trivedi PK. Regression analysis of count data. Cambridge, UK: Cambridge University Press. 1998.
22. McCracken C, Dalgard OS, Ayuso-Mateos JL, Casey P, Wilkinson G, Lehtinen V, et al. Health service use by adults with depression: community survey in five European countries. Evidence from the ODIN study. Br J Psychiatry. 2006;189:161-7.
23. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain. 2013;17:581-6.
24. Häuser W, Jung E, Erbslöh-Möller B, Gesmann M, Kühn-Becker H, Petermann F, et al. The German fibromyalgia consumer reports-a cross-sectional survey. BMC Musculoskelet Disord. 2012;13:74. doi:10.1186/1471-2474-13-74.
25. Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis. 2013;72:955-62.
26. Li YH, Wang FY, Feng CQ, Yang XF, Sun YH. Massage therapy for fibromyalgia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e89304.
27. Lima TB, Dias JM, Mazuquin BF, da Silva CT, Nogueira RM, Marques AP, et al. The effectiveness of aquatic physical therapy in the treatment of fibromyalgia: a systematic review with meta-analysis. Clin Rehabil. 2013;27:892-908.
28. Naumann J, Sadaghiani C. Therapeutic benefit of balneotherapy and hydrotherapy in the management of fibromyalgia syndrome: a qualitative systematic review and meta-analysis of randomized controlled trials. Arthritis Res Ther. 2014;16:R141.
29. Häuser W, Klose P, Langhorst J, Moradi B, Steinbach M, Schiltenwolf M, et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2010;12:R79.
30. Bernardy K, Klose P, Busch AJ, Choy EH, Häuser W. Cognitive behavioural therapies for fibromyalgia. Cochrane Database Syst Rev. 2013;9:CD009796.
31. Walker A. Confounding by indication. Epidemiology. 1996;7:335-6.